249 related articles for article (PubMed ID: 12205567)
21. [Methodological aspects of economic evaluation in pediatrics: illustration by RSV infection prophylaxis in the French setting].
Hascoet JM; Fagnani F; Charlemagne A; Vieux R; Rozé JC; Bendjenana H
Arch Pediatr; 2008 Dec; 15(12):1739-48. PubMed ID: 18990549
[TBL] [Abstract][Full Text] [Related]
22. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
Marchetti A; Lau H; Magar R; Wang L; Devercelli G
Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
[TBL] [Abstract][Full Text] [Related]
23. Cost, causes and rates of rehospitalization of preterm infants.
Underwood MA; Danielsen B; Gilbert WM
J Perinatol; 2007 Oct; 27(10):614-9. PubMed ID: 17717521
[TBL] [Abstract][Full Text] [Related]
24. Prophylaxis against respiratory syncytial virus in young children with cystic fibrosis.
Giebels K; Marcotte JE; Podoba J; Rousseau C; Denis MH; Fauvel V; Laberge S
Pediatr Pulmonol; 2008 Feb; 43(2):169-74. PubMed ID: 18085710
[TBL] [Abstract][Full Text] [Related]
25. [Guidelines for respiratory syncytial virus prophylaxis. An update].
Carbonell-Estrany X; Quero Jiménez J
An Esp Pediatr; 2002 Apr; 56(4):334-6. PubMed ID: 11927077
[TBL] [Abstract][Full Text] [Related]
26. Rehospitalisations for respiratory disease and respiratory syncytial virus infection in preterm infants of 29-36 weeks gestational age.
Resch B; Pasnocht A; Gusenleitner W; Müller W
J Infect; 2005 Jun; 50(5):397-403. PubMed ID: 15907547
[TBL] [Abstract][Full Text] [Related]
27. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
28. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
Chávez-Bueno S; Mejías A; Merryman RA; Ahmad N; Jafri HS; Ramilo O
Pediatr Infect Dis J; 2007 Dec; 26(12):1089-93. PubMed ID: 18043443
[TBL] [Abstract][Full Text] [Related]
29. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
Mitchell I; Tough S; Gillis L; Majaesic C
Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
[TBL] [Abstract][Full Text] [Related]
30. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
31. Decline in respiratory syncytial virus hospitalizations in a region with high hospitalization rates and prolonged season.
Singleton RJ; Bruden D; Bulkow LR; Varney G; Butler JC
Pediatr Infect Dis J; 2006 Dec; 25(12):1116-22. PubMed ID: 17133156
[TBL] [Abstract][Full Text] [Related]
32. Palivizumab outcomes registry data from Spain: Infección Respiratoria Infantil por Virus Respiratorio Sincitial (IRIS) Study Group.
Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S55-7; discussion S57. PubMed ID: 12671453
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
34. Health care utilisation of prematurely born, preschool children related to hospitalisation for RSV infection.
Greenough A; Alexander J; Burgess S; Bytham J; Chetcuti PA; Hagan J; Lenney W; Melville S; Shaw NJ; Boorman J; Coles S; Turner J; Pang F
Arch Dis Child; 2004 Jul; 89(7):673-8. PubMed ID: 15210503
[TBL] [Abstract][Full Text] [Related]
35. Guidelines for palivizumab prophylaxis: are they based on infant's risk of hospitalization for respiratory syncytial viral disease?
Elhassan NO; Stevens TP; Sorbero ME; Dick AW; Guillet R; Hall CB
Pediatr Infect Dis J; 2003 Nov; 22(11):939-43. PubMed ID: 14614363
[TBL] [Abstract][Full Text] [Related]
36. Palivizumab: new indication. Moderate reduction in hospitalisation rate.
Prescrire Int; 2004 Dec; 13(74):213-6. PubMed ID: 15612142
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of palivizumab in New Zealand.
Vogel AM; McKinlay MJ; Ashton T; Lennon DR; Harding JE; Pinnock R; Graham D; Grimwood K; Pattemore PK; Schousboe M
J Paediatr Child Health; 2002 Aug; 38(4):352-7. PubMed ID: 12173995
[TBL] [Abstract][Full Text] [Related]
38. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic].
Grupo de Hospitales Benazuza
An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095
[TBL] [Abstract][Full Text] [Related]
39. Respiratory syncytial virus infections in congenital heart defects--hospitalizations and costs.
Meberg A; Bruu AL
Acta Paediatr; 2006 Apr; 95(4):404-6. PubMed ID: 16720485
[TBL] [Abstract][Full Text] [Related]
40. [Respiratory syncytial virus infection in high-risk infants].
Adamovich K
Orv Hetil; 2001 Mar; 142(11):557-60. PubMed ID: 11305233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
